Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7012-7019

  Shariat, Shahrokh F ^a   Karakiewicz, Pierre I ^b   Godoy, Guilherme ^a   Karam, Jose A ^a   Ashfaq, Raheela ^a   Fradet, Yves ^c   Isbarn, Hendrik ^b   Montorsi, Francesco ^d   Jeldres, Claudio ^b   Bastian, Patrick J ^e   Nielsen, Matthew E ^f   Müller, Stefan C ^g   Sagalowsky, Arthur I ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PROGNOSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 72549108606     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2554     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-696 (Pubitemid 46621904)
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675 (Pubitemid 32120143)
4. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006;176:486-92, discussion 91-92
5. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414-2422, discussion 22.
6. Shariat SF, Karakiewicz PI, AshfaqR, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-325
7. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008;18:1-8.
8. Shariat SF, Margulis V, Karakiewicz PI. Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? Eur Urol 2008;54:11-2,
9. Eur Urol 2008;54:13-15
10. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. Eur Urol 2008;54:41-53.
11. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-2953
12. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921 (Pubitemid 27353455)
13. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589
14. Duffy MJ,O'Donovan N, Brennan DJ,Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007;249:49-60.
15. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008;26: 59-65.
16. Shariat SF, AshfaqR, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109: 1106-1113 (Pubitemid 46435389)
17. Shariat SF, AshfaqR, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37:1568-1576
18. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004;100:751-757 (Pubitemid 38176853)
19. Kren L, Brazdil J, Hermanova M, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004;12: 44-49 (Pubitemid 38332319)
20. Lehner R, Lucia MS, Jarboe EA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002;10:134-138 (Pubitemid 34553169)
21. Nakanishi K, Tominaga S, Hiroi S, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 2002; 441:559-563 (Pubitemid 35435825)
22. Salz W, Eisenberg D, Plescia J, et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res 2005;65:3531-3534 (Pubitemid 40616325)
23. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-216 (Pubitemid 40343130)
24. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-136 (Pubitemid 46158371)
25. Wuttig D, Kunze D, Fuessel S, et al. Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition? Int J Oncol 2007;30:1317-1324
26. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-49 (Pubitemid 28028045)
27. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-519
28. Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001;2: 85-97.
29. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-2546
30. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-387
31. Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A 1999;96:1457-1462 (Pubitemid 29098472)
32. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumorassociated angiogenesis. Clin Cancer Res 2003; 9:2683-2692
33. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114:1117-1127 (Pubitemid 39578701)
34. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62:2462-2467 (Pubitemid 34462718)
35. Speliotes EK, Uren A, Vaux D, Horvitz HR. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell 2000;6:211-223
36. Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001;91:2026-2032 (Pubitemid 32476366)
37. Tu SP, Jiang XH, Lin MC, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003;63:7724-7732
38. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 2003;56:826-832
39. Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003;56:441-447
40. Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat 2008;62:314-320
41. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634-635
42. Vickers AJ, Jang K, Sargent D, Lilja H, Kattan MW. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer 2008;112:1862-1868
43. Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. Stat Med 2000;19:1997-2014.
44. Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153:47-52. (Pubitemid 24379794)
45. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-9, discussion 9-500.
46. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-467
47. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369-7373
48. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-1013 (Pubitemid 41095032)
49. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014-1024 (Pubitemid 41095033)
50. Shariat SF, AshfaqR, Sagalowsky AI, Lotan Y, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177:481-487, discussion 7. (Pubitemid 46054033)
51. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-453 (Pubitemid 29362524)
52. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116:100-104 (Pubitemid 40827761)
53. Shariat SF, AshfaqR, Roehrborn CG, Slawin KM, Lotan Y. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 2005;174:2046-2050 (Pubitemid 41547021)
54. Fuessel S, Herrmann J, Ning S, et al. Chemosensitization of bladder cancer cells by survivindirected antisense oligodeoxynucleotides and siRNA. Cancer Lett 2006;232:243-254 (Pubitemid 43170974)
55. Ning S, Fuessel S, Kotzsch M, et al. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 2004;25: 1065-1071
56. Shariat SF, Zlotta AR, AshfaqR, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20:445-459 (Pubitemid 46482368)
57. Bauer KD, de la Torre-Bueno J, Diel IJ, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000;6:3552-3559
58. Braunschweig T, Chung JY, Hewitt SM. Tissue microarrays: bridging the gap between research and the clinic. Expert Rev Proteomics 2005;2: 325-336 (Pubitemid 40839744)
59. Divi RL, Dragan YP, Pitot HC, Poirier MC. Immunohistochemical localization and semiquantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 2001;22:1693-1699
60. Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002;20:3165-3175 (Pubitemid 34791107)
61. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-585